Pathogenesis, Detection & Prevention

Psoriasis pathogenesis and treatments targeting these pathways

In this video interview, Dr. Steven Feldman discusses the pathogenesis of psoriasis, why it is necessary for patients to continue to treat their condition even after seeing clearance, and how patient compliance impacts disease development.

Read More

The long road to a PsA prevention trial

About one-third of all patients with psoriasis will develop psoriatic arthritis (PsA), a condition that comes with a host of vague symptoms and no definitive blood test for diagnosis. Prevention trials could help to identify higher-risk groups for PsA, with a goal to catch disease early and improve outcomes. The challenge is finding enough participants in a disease that lacks a clear clinical profile, then tracking them for long periods of time to generate any significant data.

Read More